Celtaxsys Inc.
www.celtaxsys.com
Latest From Celtaxsys Inc.
Pipeline Watch: Phase III Starts With Bavencio, MultiStem And VT-1161
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.
Celtaxsys To Hash Out Phase III Cystic Fibrosis Endpoints With US FDA
Private start-up's acebilustat failed to improve lung function in Phase II, but the anti-inflammatory showed large numerical reductions in pulmonary exacerbations, which can be fatal.
Venture Funding Deals: BioNTech's Big Money Leads January Financings
BioNTech's $270m Series A round was the biggest start-up financing in January, but sizeable rounds also were raised by Centrexion ($67m), Eureka ($60m) and Pandion ($58m).
Execs On The Move, February 2017
Recent executive-level company changes and promotions in the biopharma, medical device and diagnostics industries.
Company Information
- Industry
- Biotechnology
- Pharmaceuticals
- Therapeutic Areas
- Dermatology
- Immune Disorders
- Inflammation
- Respiratory, Pulmonary
- Alias(es)
- Ownership
- Private
- Headquarters
-
Worldwide
-
North America
-
USA
-
USA
-
North America
- Parent & Subsidiaries
- Celtaxsys Inc.
- Senior Management
-
Greg Duncan, Pres. & CEO
Angela Walsh, VP, Fin.
Eric Springman, PhD, CSO
Sanjeev Ahuja, MD, CMO - Contact Info
-
Celtaxsys Inc.
Phone: (470) 206-0153
201 17th St., Ste. 530
Atlanta, GA 30363
USA
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice